argenex SE (NASDAQ:ARGX - Free Report) - Analysts at Wedbush reduced their Q2 2025 earnings per share estimates for shares of argenex in a research report issued to clients and investors on Monday, June 16th. Wedbush analyst D. Nierengarten now expects that the company will earn $3.43 per share for the quarter, down from their prior estimate of $4.19. Wedbush currently has a "Outperform" rating and a $715.00 price objective on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q3 2025 earnings at $4.49 EPS, Q4 2025 earnings at $5.43 EPS, Q1 2026 earnings at $6.58 EPS, Q2 2026 earnings at $7.71 EPS, Q3 2026 earnings at $7.21 EPS, FY2026 earnings at $29.33 EPS, FY2027 earnings at $38.72 EPS and FY2028 earnings at $53.89 EPS.
argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%.
Several other research analysts have also issued reports on ARGX. Citigroup reiterated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Robert W. Baird raised shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective on the stock in a research note on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Guggenheim dropped their price target on shares of argenex from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Sanford C. Bernstein raised shares of argenex from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $709.18.
Read Our Latest Stock Analysis on argenex
argenex Price Performance
ARGX stock opened at $540.71 on Wednesday. The company's 50-day moving average is $587.09 and its 200-day moving average is $610.67. The stock has a market capitalization of $33.02 billion, a PE ratio of 33.36, a price-to-earnings-growth ratio of 0.96 and a beta of 0.39. argenex has a 1 year low of $377.48 and a 1 year high of $678.21.
Institutional Investors Weigh In On argenex
Hedge funds have recently made changes to their positions in the business. Point72 Europe London LLP bought a new stake in shares of argenex during the 4th quarter worth $5,839,000. Ameriprise Financial Inc. raised its position in argenex by 10.0% in the fourth quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after acquiring an additional 639 shares during the period. Jones Financial Companies Lllp raised its position in argenex by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after acquiring an additional 61 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of argenex by 13.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,538 shares of the company's stock worth $946,000 after purchasing an additional 181 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of argenex by 1.9% in the 4th quarter. Rhumbline Advisers now owns 3,608 shares of the company's stock worth $2,219,000 after purchasing an additional 66 shares during the period. 60.32% of the stock is currently owned by institutional investors.
About argenex
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
